65 results about "Sympathetic nervous system" patented technology

The invention relates to the technical field of emotional robots, and discloses an embracing emotional robot which comprises an inner shell, low-cost and high-simulation breathing simulation is achieved through cooperative control of an air pump and an air valve, and the embracing emotional robot is designed by combining simulation body temperature brought by a heating piece and synchronous action of a rotatable arm. The emotion robot can naturally rotate forwards when being embraced and is matched with simulated respiration and simulated body temperature, so that the immersion and emotion interaction experience of a user are remarkably improved; the operation cycle of the air pump strictly follows biological breathing characteristics, the inspiration stage accounts for 2 / 3 of the breathing cycle, the speed of the inspiration stage changes fast and slow, the expiration stage accounts for 1 / 3 of the expiration stage, smooth pressure relief is achieved through the air valve, and the highly-simulated breathing mode can effectively guide a user to breathe synchronously, so that parasympathetic nerves are activated, the anxiety level and heart rate fluctuation are reduced, and the user experience is improved. And the whole structure adopts a modular design, complex functions such as breathing simulation, embracing and body temperature simulation can be realized, the maintenance is convenient, and the device is particularly suitable for long-term accompanying scenes.

The invention discloses a VR emotion quantitative management method and system based on physical and psychological interaction, and relates to the field of psychotherapy, and the method comprises the steps: collecting the heart rate variability data, the electrodermal response data and the EEG alpha wave power data of a user in a resting state, and obtaining the EEG alpha wave power data of the user based on the heart rate variability data and the electrodermal response data; generating color, density and physical boundary parameters of the initial emotion energy field; and rendering a dynamic emotion energy field in the VR environment according to the initial emotion energy field parameters, and detecting the distance change between the user and the dynamic emotion energy field through a field density growth algorithm. According to the method, heart rate variability, electrodermal response and EEG alpha wave data are fused by adopting an S-shaped curve function to generate emotion energy field parameters, accurate mapping of physiological states and virtual environments is established, emotion recognition sensitivity is improved, treatment efficiency is improved, field density attenuation rate is dynamically controlled innovatively through parasympathetic nerve activation degree, and the treatment effect is improved. And the synergistic effect of behavior intervention and nerve regulation is realized.

To provide a program that allows a measurement object person to easily check his or her state in detail using a smartphone or the like by various expressions.SOLUTION: A moving image acquisition unit 111 acquires moving image data showing a moving image that a user has taken of his or her face by a camera 16. The acquired moving image data is accumulated in a moving image DB 121 of a memory 12. A pulse measuring unit 112 reads out the moving image data from the moving image DB 121, and measures vital values including a pulse on the basis of the moving image data. A ratio calculation unit 113 calculates a ratio of a sympathetic nerve to a parasympathetic nerve on the basis of the pulse included in the measured vital values. An activity calculation unit 114 calculates the activity of the entire autonomous nerve on the basis of the pulse included in the measured vital values. A plotting part 115 plots a state of the user's nervous system indicated by LF / HF and TP on a plane with the LF / HF and the TP as two axes.SELECTED DRAWING: Figure 10

Methods, devices and systems are described for decreasing the activity of the sympathetic nervous innervation to and from the lungs and the vessels supplying the lungs to treat pulmonary medical conditions such as asthma. In one embodiment, the method may involve advancing an intravascular instrument to a target location in a blood vessel within the intercostal vasculature to ablate either or both the sympathetic afferent and efferent nerves lying within the paravertebral gutter including the visceral fibers that travel to the cardiothoracic cavity and abdominopelvic viscera and the T1 to T4 / 5 sympathetic chain. In another embodiment, an intravascular instrument may be advanced to the bronchial vessels to ablate either or both the sympathetic afferent and efferent nerves in and around the posterior pulmonary plexus. In one embodiment the ablative agent is a neurolytic agent delivered in a gel. This approach may be utilized to treat other cardiac and pulmonary diseases.

Disclosed herein are systems and methods for locating and identifying nerves innervating the wall of arteries such as the renal artery. The present invention identifies areas on vessel walls that are innervated with nerves; provides indication on whether energy is delivered accurately to a targeted nerve; and provides immediate post-procedural assessment of the effect of energy delivered to the nerve. The methods includes evaluating a change in physiological parameters after energy is delivered to an arterial wall; and determining the type of nerve that the energy was directed to (sympathetic or parasympathetic or none) based on the evaluated results. The system includes at least a device for delivering energy to the wall of blood vessel; sensors for detecting physiological signals from a subject; and indicators to display results obtained using said method. Also provided are catheters for performing the mapping and ablating functions.

This utility model relates to an electronic device. The electronic device according to this utility model is characterized by comprising a processor that acquires a heart rate variability signal related to the heart rate of a user sitting on the massage chair from a sensor mounted on the massage chair; the processor determines the user's stress level or parasympathetic nervous system activity based on the heart rate variability signal and the user's breathing rate; the processor determines a suitable target breathing rate for the user based on the stress level or the parasympathetic nervous system activity; and the processor controls the massage chair to induce the user to breathe at the target breathing rate. According to this utility model, the electronic device controls the massage chair based on the target breathing rate, thereby inducing the user to breathe at the determined target breathing rate.

The present technology provides systems and methods for delivering electrical stimulation having relatively long pulse widths to a patient’s spinal cord region to treat autonomic nervous system dysfunction. For example, some embodiments include delivering an electrical therapy signal having individual pulses with pulse widths of between about 2 milliseconds and about 10 seconds. The electrical therapy signals may treat autonomic nervous system dysfunction by normalizing activity of the patient’s parasympathetic nervous system, normalizing activity of the patient’s sympathetic nervous system, and / or normalizing a balance of activity between the patient’s parasympathetic and sympathetic nervous systems.

This application provides a method, device, electronic device, and computer-readable storage medium for detecting drowsiness. The method includes: acquiring user physiological data; the user physiological data includes human parasympathetic nerve activation parameters and body activity state parameters; determining whether the user is in an awake state based on the human parasympathetic nerve activation parameters and body activity state parameters; and, if the user is in an awake state, determining whether the user is in a drowsy state based on the human parasympathetic nerve activation parameters. Determining whether a user is in a drowsy state using human parasympathetic nerve activation parameters and body activity state parameters can improve the accuracy of drowsiness detection.

A method of cardiac treatment to provides a synergetic therapeutic effect of lowering the hyperactive sympathetic response observed in microvascular disease (MVD) and heart failure (HF) pathologies and promoting cardiac remodeling of left ventricular hypertrophy in a patient. The method may include ablating renal sympathetic nerves of the patient to reduce sympathetic afferent and efferent activity to the kidney, thereby reducing blood pressure, delivering cardiac pacing to induce remodeling of hypertrophy of the left ventricle of the patient's heart, and stimulating a vagus nerve of the patient to induce an anti-inflammatory reflex in the patient's heart. The method may include ablating renal sympathetic nerves of the patient to reduce sympathetic afferent and efferent activity to the kidney, thereby reducing blood pressure, and stimulating carotid baroreceptors of the patient to downregulates sympathetic tone and upregulates parasympathetic tone.

The present application provides a mood state monitoring method, device, and storage medium. The method obtains autonomic nervous activity signals from a target individual; the autonomic nervous activity signals include multiple time-segmented autonomic nervous activity signals; extracts target sequences from the multiple time-segmented autonomic nervous activity signals to obtain multiple time-segmented physiological data; and calculates and compares the multiple time-segmented physiological data based on a preset feature space to determine the target individual's mood state. The preset feature space includes a preset stress level assessment feature space, a preset parasympathetic nervous system forced regulation state detection feature space, and a preset mood state assessment feature space. This method enables all-day mood state monitoring of a population, thereby effectively and completely inferring the population's mood state.

The application of CpG oligonucleotides in drugs for diabetic cardiac autonomic neuropathy: Experiments have confirmed that CpG oligonucleotide 1826 can reduce the activation of satellite glial cells in the stellate ganglion and the expression of inflammatory cytokines, inhibit the expression of purine 2Y12 receptors, and reduce lipid peroxidation damage to alleviate ferroptosis in stellate ganglion neurons, thereby improving cardiac autonomic nerve function. Examples of CpG oligonucleotide 1826 demonstrate that CPG-ODN with anti-inflammatory effects or with anti-damage protective effects on the sympathetic nervous system has preventive and therapeutic effects in diabetic cardiac autonomic neuropathy and sympathetic nerve injury-related diseases.

This invention discloses a traditional Chinese medicine composition for improving hypertension, belonging to the field of traditional Chinese medicine compound preparation technology. This invention targets the core pathogenesis of hypertension caused by phlegm-dampness obstruction and peripheral microcirculation disorders, leading to abnormal activation of the hypothalamic-sympathetic-cardiac axis and compensatory cardiac hypertensive. The treatment principle is to resolve phlegm and dampness, and invigorate blood circulation. It is formulated with nutmeg, allium macrostemon, amomum villosum, peach kernel, safflower, platycodon grandiflorus, angelica dahurica, and tangerine peel. This combination can dredge the meridians, improve peripheral blood supply, and alleviate cardiac compensatory pumping, thus addressing hypertension caused by phlegm-dampness obstruction at its root. The formula is scientifically formulated, highly safe, and easy to prepare, making it suitable for long-term treatment and industrial promotion.

To provide an aromatherapy support method and support system that enables a therapist to fully fulfill his / her original role without placing a burden on the therapist. [Solution] The system includes the steps of: conducting an autonomic nervous system analysis on the client to determine whether the client belongs to a sympathetic dominant, parasympathetic dominant, or well-balanced type; determining the client's complaints; transmitting basic information including the determined client type and complaint information to a system server; selecting the most suitable essential oils in the system server based on search keywords created from the basic information imported; calculating the blend ratio of the selected essential oils; and displaying the calculated blend ratio information on the screen of the therapist terminal.

The telemedicine system includes a gateway for transmitting monitoring information including a stimulation signal and a biosignal corresponding to the stimulation signal to a cloud; and a server for extracting the stimulation signal and the biosignal from the transmitted monitoring information, providing the extracted stimulation signal and biosignal as inputs of a pre-stored artificial intelligence machine learning algorithm-based stimulation control model, regenerating the biosignal as an output of the stimulation control model into a stimulation signal to be regulated for the balance between sympathetic and parasympathetic nerves, and feeding back the regenerated stimulation signal to a personalized vagus nerve stimulation and pulse electromagnetic field treatment device.

Systems and methods for treating Inflammatory Bowel Disease (IBD) using neuromodulation are described herein. For example, IBD can be treated by delivering an electrical signal to one or more sacral nerves of a patient via a signal delivery device positioned proximate one or more of the patient's sacral nerves. In some embodiments, the electrical signal can modulate neural activity in the patient, which may in turn reduce inflammation in the patient by altering an imbalance between the patient's sympathetic nervous system and parasympathetic nervous system, and / or modifying a threshold for an inflammatory response in the gastrointestinal system.

Systems, methods and devices for controlled sympathectomy procedures for neuromodulation in the treatment of subjects having neoplastic conditions are disclosed. Systems, methods, and devices for interventionally treating a cancerous tumor and cancer related pain are disclosed.

A moving image acquisition unit (111) acquires moving image data indicating a moving image of the user's face captured by the user using a camera (16). The acquired moving image data is accumulated in a moving image DB (121) of a memory (12). A pulse measurement unit (112) reads the moving image data from the moving image DB (121), and measures vital values including pulse on the basis of the moving image data. A ratio calculation unit (113) calculates the ratio of sympathetic nerves and parasympathetic nerves on the basis of the pulse included in the measured vital values. An activity calculation unit (114) calculates the activity of the autonomic nerves overall on the basis of the pulse included in the measured vital value. A plotting unit (115) plots the state of the user's nervous system indicated by LF / HF and TP on a plane in which LF / HF and TP are the two axes.

An object of the present invention is to provide a drug evaluation method using myocardial cells, which can stably evaluate an effect of a drug such as a muscarinic receptor agonist, an adrenergic receptor inhibitor or a muscarinic receptor inhibitor on a heart rate; and a reagent and a kit for carrying out the drug evaluation method. According to the present invention, there is provided a drug evaluation method including: treating myocardial cells with a culture medium containing a physiologically active substance of a sympathetic nervous system and / or a physiologically active substance of a parasympathetic nervous system; bringing a drug into contact with the myocardial cells treated as above; and evaluating an effect of the drug on a heart rate of the myocardial cells.

This application discloses the application of PLAC8 as a target in the preparation of tumor therapeutic drugs, involving the field of biomedical technology. This application clarifies that the "sympathetic nervous system-β2-AR-PLAC8-cholesterol metabolism-M2 polarization" pathway is the core driving pathway for stress-related tumor progression and chemotherapy resistance. It reveals the molecular mechanism by which PLAC8 inhibits cholesterol synthesis through phosphorylation at the S67 site, binding to the N-terminal domain of SREBP2, recruiting OGT to mediate SREBP2O-GlcNAc glycosylation. Through strategies such as gene silencing, β2-AR antagonist intervention, and targeted delivery of siPLAC8 via mannose-modified lipid nanoparticles (LNPs), the application achieved the effects of inhibiting M2 macrophage accumulation, inhibiting tumor growth, and reversing chemotherapy resistance in various tumor models, including gallbladder cancer, intrahepatic cholangiocarcinoma, and prostate cancer. Furthermore, the LNPs delivery system showed no significant toxicity. This research provides a novel therapeutic target centered on PLAC8 and a safe and effective targeted intervention strategy for stress-related tumors, highlighting its clinical translational value.

Provided is a method for spraying a fragrance into a space, the method being executed by a control unit, wherein a first fragrance that stimulates the parasympathetic nerves of a user (50) present in the space (SP) and a second fragrance that stimulates the sympathetic nerves of the user (50) are sprayed. The control unit sprays the first fragrance, stops spraying the first fragrance, and sprays the second fragrance after at least the lingering time of the first fragrance has passed.

Devices for therapeutic nasal neuromodulation and associated systems and methods are disclosed herein. A system for therapeutic neuromodulation in a nasal region configured in accordance with embodiments of the present technology can include, for example, a shaft and a therapeutic element at a distal portion of the shaft. The shaft can locate the distal portion intraluminally at a target site inferior to a patient's sphenopalatine foramen. The therapeutic element can include an energy delivery element configured to therapeutically modulate postganglionic parasympathetic nerves at microforamina of a palatine bone of the human patient for the treatment of rhinitis or other indications. In other embodiments, the therapeutic element can be configured to therapeutically modulate nerves that innervate the frontal, ethmoidal, sphenoidal, and maxillary sinuses for the treatment of chronic sinusitis.

The present technology provides systems and methods for delivering electrical stimulation having relatively long pulse widths to a patient’s spinal cord region to treat autonomic nervous system dysfunction. For example, some embodiments include delivering an electrical therapy signal having individual pulses with pulse widths of between about 2 milliseconds and about 10 seconds. The electrical therapy signals may treat autonomic nervous system dysfunction by normalizing activity of the patient’s parasympathetic nervous system, normalizing activity of the patient’s sympathetic nervous system, and / or normalizing a balance of activity between the patient’s parasympathetic and sympathetic nervous systems.

Methods of improving ARDS by regulating a stellate ganglion is provided herein. Methods of improving a hypercoagulation state are also provided by regulating the sympathetic nervous system.

Light is fundamental for biological life, with most mammals possessing light-sensing photoreceptors in various organs. Opsin3 is highly expressed in adipose tissue which has extensive communication with other organs, particularly with the brain through the sympathetic nervous system (SNS). Our study reveals a new light-triggered crosstalk between adipose tissue and the hypothalamus. Direct blue-light exposure to subcutaneous white fat improves high-fat diet-induced metabolic abnormalities in an Opsin3-dependent manner. Metabolomic analysis shows that blue light increases circulating levels of histidine, which activates histaminergic neurons in the hypothalamus and stimulates brown adipose tissue (BAT) via SNS. Blocking central actions of histidine and denervating peripheral BAT blunts the effects of blue light. Human white adipocytes respond to direct blue light stimulation in a cell-autonomous manner, highlighting the translational relevance of this pathway. Together, these data demonstrate a light-responsive metabolic circuit involving adipose-hypothalamus communication, offering a potential strategy to alleviate obesity-induced metabolic abnormalities.

A method for treating a heart failure patient by ablating a nerve of the splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method including: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying simulation energy after the ablation and observing hemodynamic effects.

To provide a bicarbonate bath additive that allows reduction of chemical stress to sustain a parasympathetic-dominant condition, and causes capillaries to dilate to double their size so as to quickly enhance blood circulation; and its production method.SOLUTION: The bicarbonate bath additive is produced by using materials comprising a bicarbonate salt (sodium hydrogen carbonate), an organic acid (citric acid), a lubricant (sodium alkanesulfonates having 14 to 18 carbon atoms, sodium tetradecenesulfonate, sodium n-octanesulfonate), and chlorine-neutralizing compounds (L-ascorbate, thiosulfate, sulfite, tea catechin, erythorbate), wherein a weight ratio of the organic acid (citric acid) to the bicarbonate salt (sodium hydrogen carbonate) is 1 / 8 to 2 / 7.SELECTED DRAWING: Figure 3

Devices for therapeutic nasal neuromodulation and associated systems and methods are disclosed herein. A system for therapeutic neuromodulation in a nasal region configured in accordance with embodiments of the present technology can include, for example, a shaft and a therapeutic element at a distal portion of the shaft. The shaft can locate the distal portion intraluminally at a target site inferior to a patient's sphenopalatine foramen. The therapeutic element can include an energy delivery element configured to therapeutically modulate postganglionic parasympathetic nerves at microforamina of a palatine bone of the human patient for the treatment of rhinitis or other indications. In other embodiments, the therapeutic element can be configured to therapeutically modulate nerves that innervate the frontal, ethmoidal, sphenoidal, and maxillary sinuses for the treatment of chronic sinusitis.

The purpose of the present invention is to provide a method for evaluating a drug using myocardial cells and with which it is possible to stably evaluate the effect of a drug such as a muscarinic receptor agonist, an adrenergic receptor inhibitor, and a muscarinic receptor inhibitor on the heart rate. And a reagent and a kit for performing the method for evaluating the drug. According to the present invention, provided is a method for evaluating a drug, comprising: a step for treating myocardial cells with a culture medium containing a physiologically active substance of the sympathetic nervous system and / or a physiologically active substance of the parasympathetic nervous system; a step in which a drug is brought into contact with the treated myocardial cells; and evaluating the influence of the drug on the heart rate of the myocardial cells.

Systems, methods and devices for controlled sympathectomy procedures for neuromodulation in the treatment of subjects having neoplastic conditions are disclosed. Systems, methods, and devices for interventionally treating a cancerous tumor and cancer related pain are disclosed.

The invention relates to the technical field of emotion regulation, in particular to an emotion regulation method and system by combining cold and heat alternating stimulation with parasympathetic nerve activation, and the method comprises the steps: obtaining the physiological signal data of a user in real time; inputting the high-frequency power of the heart rate variability into a pre-trained parasympathetic nerve activity quantitative model, and calculating a current vagus nerve tension parameter of the user; determining the anxiety level of the user based on the vagus nerve tension parameter, and dynamically determining a target alternate cooling and heating stimulation parameter of the Peltier element according to the anxiety level of the user; inputting the target alternate cooling and heating stimulation parameter of the Peltier element into a preset skin thermal injury model, and dynamically adjusting the power output of the Peltier element; and according to the real-time change rate of the skin sympathetic reaction data, feeding back and adjusting a target cooling and heating alternating stimulation parameter of the Peltier element until the high-frequency power of the heart rate variability reaches a target threshold value. The method has the effect of improving the emotion regulation efficiency.